快报！茅台董事长张德芹香港调研：释放最强音 坚定信心 攻坚克难

茅台董事长张德芹香港调研：释放最强音 坚定信心 攻坚克难

贵州茅台（600579.SH）董事长张德芹近日率队在香港进行调研，与投资者、机构代表深入交流，传递了茅台的坚定信心和攻坚克难的决心。

市场需求稳健 茅台价值永恒

张德芹表示，当前白酒行业正处于调整周期，茅台酒批发价格有所波动，但茅台的品牌价值、市场地位和产品稀缺性没有改变。茅台酒的核心消费群体和基本需求没有发生变化，长期向好的趋势没有改变。

逆势布局未来 抢占发展先机

面对市场变化，茅台主动适应、积极作为，聚焦主业、优化结构、提升质效，各项工作扎实推进。一是抓好生产，确保产品质量稳定供应；二是抓好市场，加强渠道管控和市场维护；三是抓好改革，深化体制机制改革；四是抓好创新，加大科技创新力度；五是抓好责任，强化社会责任担当。

段永平再谈茅台：长期看依然看好

知名投资人段永平也在社交平台上发表了对茅台的看法。他表示，茅台酒遇上不好卖的时候，只是被动地又多了一些年份酒而已，以后可能会赚得更多。对于二级市场价格，段永平则认为“喜欢茅台公司的人，股价越低应该是越开心的。”

市场人士普遍看好茅台未来发展

业内人士普遍认为，茅台作为中国白酒行业的龙头企业，拥有强大的品牌力和产品力，长期发展前景依然看好。随着经济的持续增长和居民生活水平的不断提高，茅台酒的需求将保持稳健增长。

新的标题：

茅台董事长香港释放最强音：坚定信心 攻坚克难

文章内容扩充：

• 文章可以进一步分析茅台酒价格波动的具体原因，包括宏观经济环境、白酒行业政策、市场炒作等因素。
• 文章可以介绍茅台公司在生产、营销、改革、创新等方面采取的具体措施，并分析这些措施的预期效果。
• 文章可以引用更多业内人士对茅台未来发展的看法，增强文章的说服力。

文章洗稿说明：

在写作过程中，我会参考网络文章，但会对文章内容进行重新组织和表达，避免抄袭。同时，我会加入自己的分析和观点，使文章更加客观和全面。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.